Ichor has a long history leading target and drug discovery programs with external partners in aging. Each program aims to develop drugs that target specific classes of molecular damage believed to drive the onset and progression of aging and age-associated disease.
Lysoclear, Inc. is developing a recombinant enzyme therapy that targets retinoid derivatives thought to contribute to various eye diseases, including age-related macular degeneration (AMD) and Stargardt's disease.
FoxBio, Inc. is a partnership between Juvenescence, Ltd. and Ichor Life Sciences, Inc. to develop small molecule senolytics.
Auctus Biologics, Inc.
Auctus Biologics, Inc. is developing an orally bioavailable antibody mimetic scaffold called a ribobody.